ArticleEuropean journal of nuclear medicine and molecular imaging2020
Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism.
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
68Ga-Pentixafor PET/CT for the Subtyping Diagnosis of Primary Aldosteronism: A Prospective Diagnostic Accuracy Study
Clinical Study of Chemokine Receptor 4 (CXCR4)-Mediated Precision Targeting of 18F for the Diagnosis of Aldosteronism in Primary Aldosteronism
A Single Center Study on the Evaluation of Diagnostic Efficacy of CXCR4 Targeted PET Imaging in Primary Aldosteronism
68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling to Determine Treatment in Primary Aldosteronism: A Multicenter Randomized Clinical Trial
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- AVS-referenced diagnostic performance ofFrontiers in endocrinology · 2026Pooled it
- Clinical value of CXCR4-targeted PET-CT in primary aldosteronism: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- DeltaAnnals of surgical oncology · 2026Article
- CXCR4 reduces aldosterone synthesis via regulating CYP11B2 expression.Genes & diseases · 2026Article
- One-stop evaluation using [Japanese journal of radiology · 2026Article
- Article
- Clinical value of multi-time-pointEndocrine · 2026Article
- Development and validation of a CXCR4-targetedEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Article
- A Novel Non-Invasive Diagnostic Tool for Determining the Subtype of Primary Aldosteronism UsingWorld journal of nuclear medicine · 2026Article
- Machine learning-based model for prediction of KCNJ5 mutation in unilateral primary aldosteronism based on [EJNMMI research · 2026Article
- Case Report: Five positive lesions on bilateral adrenal glands detected by a singleFrontiers in nuclear medicine · 2026Article
- 68 Ga-pentixafor PET/CT versus adrenal venous sampling in guiding surgical management for primary aldosteronism: a prospective cohort study on postoperative outcomes.International journal of surgery (London, England) · 2026Article
- Real world experience with [Frontiers in endocrinology · 2026Article
- The utility of 68Ga-pentixafor PET/CT in superselective adrenal artery embolization(SAAE) for treating aldosterone adenomas.European journal of nuclear medicine and molecular imaging · 2026Article
- Physiological biodistribution ofJapanese journal of radiology · 2026Article
- The CXCR4-targeted theranostics era: a comprehensive review of a decade of progress (2015-2025).Theranostics · 2026Review
- Identifying unilateral aldosterone-producing adenomas using published algorithms and imaging: a systematic review and meta-analysis.Endocrine connections · 2025Article
- Added value of multiparametric MRI for diagnosing subcentimeter functional adrenal nodules in primary aldosteronism using CXCR4-targeted PET/MRI.European journal of nuclear medicine and molecular imaging · 2025Article
- Advances in Endocrine Tumor PET Imaging Targeting CXCR4 and GLP-1.Seminars in nuclear medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIt is challenging to differentiate unilateral aldosterone-producing adenoma (APA) from bilateral idiopathic adrenal hyperplasia (IAH) and nonfunctional adrenal adenoma (NFA) in primary aldosteronism (PA). In a first primarily ex vivo study detection, CXC chemokine receptor type 4 (CXCR4) expression has been shown to be a valuable tool for the detection of APA. In this study, we aimed to clinically evaluate CXCR4 imaging with
methodsWe prospectively recruited 36 patients with clinical suspicion of PA. All patients underwent
resultsThirty-nine adrenal lesions in 36 patients were found; 25 APA, 4 IAH, and 10 NFA according to histopathology and clinical assessment. Sensitivity, specificity, and accuracy of
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.